FDA approves Keytruda in cervical cancer

Merck & Co. Inc. (NYSE:MRK) said FDA granted accelerated approval to Keytruda pembrolizumab to treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapy in patien...